Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
SOREDEX
Schiller

Medtronic Buys Tyrx Antibacterial Envelope Manufacturer

By HospiMedica International staff writers
Posted on 13 Jan 2014
Startup company Tyrx (Monmouth Junction, NJ, USA), which manufactures bioresorbable envelopes for implanted medical devices, is now a part of Medtronic (Minneapolis, MN, USA), the world's largest medical device company.

The acquisition supports Medtronic's expansion of its medical device product offerings to include broader healthcare services and solutions, providing meaningful clinical outcomes and economic value for hospitals, physicians, patients, and payers. TYRX brings to Medtronic the AIGISRx R fully resorbable antibacterial envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs), and the AIGISRx N antibacterial envelope, used with spinal cord neurostimulators.

The bioresorbable envelopes use a combination of two antibiotic drugs: Minocycline and Rifampin. Minocycline is a tetracycline-class antibiotic commonly used to treat skin acne, among other things; Rifampin is commonly used to treat tuberculosis. Both drugs have different modes of action, and working together target roughly 80% of the germs, which can be introduced during surgery, including Methicillin Resistant Staphylococcus aureus (MRSA) and a number of other pathogens.

“While the risk of infection from an implanted pacemaker or defibrillator is low for most patients, repeated operative procedures after the initial device implant are associated with a substantial incremental risk of infection. This is estimated to cost the US healthcare system more than one billion dollars per year,” said Pat Mackin, president of the cardiac rhythm disease management business and senior vice president at Medtronic. “TYRX has developed an innovative, proven technology to reduce infection risk, making the procedure safer for patients and removing significant costs from the healthcare system.”

“We look forward to joining Medtronic as part of a combined portfolio that can positively impact outcomes for patients by reducing implant-related infections, and bring value to our customers,” said Robert White, president and CEO of Tyrx.

The all-cash transaction includes an initial payment of USD 160 million plus potential earn out and performance based milestone payments.

Related Links:

Tyrx
Medtronic
Antibacterial Envelope Protects Cardiac Implants




CardioComm Solutions
Dunlee
Anetic Aid

Channels

Critical Care

view channel
Image: Solid microneedles coated with Bevacizumab (syringe for scale) (Photo courtesy of the Georgia Institute of Technology).

Tiny Needles Reshape Major Eye Disease Treatment

Novel microneedles allow dramatic dose sparing when compared to subconjunctival and topical administration of drugs directly into the eye. Developed by researchers at the Georgia Institute of Technology... Read more

Women's Health

view channel

Women with PTSD Face Higher Pregnancy Risk

Suffering from post-traumatic stress disorder (PTSD) significantly increases a pregnant woman's risk of premature birth, according to a new study. Researchers at Stanford University (CA, USA) conducted a study to identify antenatal PTSD status and spontaneous preterm delivery in a retrospective cohort (2000-2012).... Read more

Health IT

view channel

Wikipedia Page Views Could Predict Disease Outbreaks

A new study suggests that Wikipedia access data could be an effective tool for forecasting disease outbreaks up to a month in advance. Researchers at the Los Alamos National Laboratory (NM, USA) reviewed access logs to disease-related Wikipedia pages between 2010 and 2013. They mapped the languages the information was... Read more
 

Events

26 Nov 2014 - 28 Nov 2014
01 Dec 2014 - 05 Dec 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.